Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9HC10

UPID:
OTOF_HUMAN

ALTERNATIVE NAMES:
Fer-1-like protein 2

ALTERNATIVE UPACC:
Q9HC10; B4DJX0; B5MCC1; B9A0H6; Q53R90; Q9HC08; Q9HC09; Q9Y650

BACKGROUND:
The protein Otoferlin, alternatively known as Fer-1-like protein 2, plays a crucial role in the control of neurotransmitter release at cochlear synapses. It is essential for the Ca(2+)-triggered synaptic vesicle fusion in inner and outer hair cells of the cochlea, indicating its significant function in hearing.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting Otoferlin are linked to severe auditory diseases, including autosomal recessive deafness and auditory neuropathy. The protein's involvement in these conditions highlights its potential as a target for developing treatments aimed at restoring hearing function in affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.